Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This clinical study is evaluating a drug called BT7480 alone and in combination with
nivolumab in participants with advanced solid tumors associated with Nectin-4 expression.
The main goals of the study are to:
- Find the recommended dose of BT7480 that can be given safely to participants alone and
in combination with nivolumab
- Learn about the side effects and effectiveness of BT7480 alone and in combination with
nivolumab
- Learn about the effect BT7480 has on the body and how BT7480 is cleared by the body
- Learn about the side effects and effectiveness of BT7480 in patients with reduced kidney
function